FDA Brief

Warning letters Drugs

FDA warning letter to

MedisourceRx

MediumIssued Dec 12, 2025Posted Feb 24Center for Drug Evaluation and Research (CDER)

MedisourceRx failed to report a serious adverse event and had inadequate procedures, so its compounded drugs lost legal exemptions.

What happened

FDA inspected MedisourceRx from May 27 to June 10, 2025, and found it did not submit an adverse event report identified in Complaint Log # C25004 and did not adequately define a “serious” adverse event in its procedures under 21 CFR 310.305(b). Because the facility did not meet all conditions for registering as an outsourcing facility under section 503B (the outsourcing-facility exemption law), FDA says its compounded drugs are not eligible for that section’s exemptions and are unapproved new drugs and misbranded.

What FDA found

  1. The company did not submit a required adverse event report for a complaint logged as C25004.

    FDCA § 503B(b)(5) [21 U.S.C. § 353b(b)(5)]; § 301(ccc)(3)
  2. Its written procedures do not adequately define what counts as a “serious” adverse event.

    21 CFR 310.305(b)
  3. It compounded drug products without FDA-approved applications.

    FDCA §§ 505(a), 301(d) [21 U.S.C. § 331(d)]
  4. Its labels lacked adequate directions for use because the drugs are for conditions that laypeople cannot safely diagnose and treat.

    FDCA § 502(f)(1) [21 U.S.C. § 352(f)(1)]; § 301(a)

What FDA wants

FDA asks MedisourceRx to notify it in writing within 15 working days of the steps taken to correct the violations, with an explanation and supporting documents; if it cannot finish in that time, it must state why and give a completion date.

Who should pay attention

  • other 503B outsourcing facilities
  • compounding pharmacies with adverse-event reporting duties
  • buyers of compounded drugs such as clinics and health systems

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Naseem A. Jaffrani, M.D.

    FDA says clinical investigator Dr. Naseem Jaffrani failed to report serious adverse events to sponsors within 24 hours in two drug trials.

    High risk
  2. ProRx LLC

    ProRx LLC, an outsourcing facility, made sterile compounded drugs under insanitary conditions and without required 503B eligibility.

    High risk
  3. Apothecary Pharma, LLC

    FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.

    High risk
  4. Novo Nordisk Inc.

    FDA warns Novo Nordisk over failures to report and investigate serious unexpected adverse drug experiences for drugs including semaglutide.

    High risk